{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:35:27Z","timestamp":1791070527394,"version":"4.1.0"},"reference-count":59,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1533,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1111\/j.1528-1167.2011.03140.x","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T17:26:33Z","timestamp":1308677193000},"page":"1894-1904","source":"Crossref","is-referenced-by-count":88,"title":["In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein"],"prefix":"10.1111","volume":"52","author":[{"given":"Chunbo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,6,21]]},"reference":[{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"32167","DOI":"10.1074\/jbc.273.48.32167","article-title":"Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain","volume":"273","author":"Bakos","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuropharm.2006.07.038","article-title":"Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein","volume":"52","author":"Baltes","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2997","article-title":"Key factors in the discovery and development of new antiepileptic drugs","volume":"9","author":"Bialer","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB4|cit4","volume-title":"Fast facts: epilepsy","author":"Brodie","year":"2005"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1124\/jpet.105.085514","article-title":"Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity","volume":"314","author":"Clinckers","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0928-0987(00)00141-X","article-title":"Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression","volume":"12","author":"Crespi","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/10611860600720814","article-title":"Limited P-glycoprotein mediated efflux for anti-epileptic drugs","volume":"14","author":"Crowe","year":"2006","journal-title":"J Drug Target"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/jps.21580","article-title":"Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB","volume":"98","author":"Di","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/dmd.107.017434","article-title":"In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system","volume":"36","author":"Feng","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"Efficacy and safety of 800 and 1200\u2003mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.mp.4001793","article-title":"Treatment-resistant bipolar disorder","volume":"11","author":"Gitlin","year":"2006","journal-title":"Mol Psychiatry"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"12163","DOI":"10.1016\/S0021-9258(18)37730-5","article-title":"The multidrug transporter, a double-edged sword","volume":"263","author":"Gottesman","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.taap.2008.02.026","article-title":"In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression","volume":"230","author":"Han","year":"2008","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2006.10.007","article-title":"A primer on the mechanics of P-glycoprotein the multidrug transporter","volume":"55","author":"Hennessy","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1017\/S1461145704004651","article-title":"A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder","volume":"7","author":"Hirschfeld","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neulet.2009.01.079","article-title":"Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid","volume":"453","author":"H\u00f6cht","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0924-9338(02)00696-X","article-title":"Antiepileptic drugs in schizophrenia: a review","volume":"17","author":"Hosak","year":"2002","journal-title":"Eur Psychiatry"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1124\/dmd.107.018176","article-title":"In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier","volume":"36","author":"Hsiao","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB20|cit20","first-page":"CD003499","article-title":"Antiepileptics for aggression and associated impulsivity","volume":"2","author":"Huband","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FPC.0b013e3282f85e36","article-title":"Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs","volume":"18","author":"Hung","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim Biophys Acta"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pnpbp.2008.10.012","article-title":"Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial","volume":"33","author":"Juruena","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.pnpbp.2007.09.003","article-title":"ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder","volume":"32","author":"Kato","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.1135308","article-title":"A \u201csilent\u201d polymorphism in the MDR1 gene changes substrate specificity","volume":"315","author":"Kimchi-Sarfaty","year":"2007","journal-title":"Science"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00003088-200746040-00001","article-title":"The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications","volume":"46","author":"Klotz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1059-1311(05)80001-9","article-title":"A computational quantitative structure-activity relationship study of carbamate anticonvulsants using quantum pharmacological methods","volume":"7","author":"Knight","year":"1998","journal-title":"Seizure"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/hup.470070209","article-title":"Possible relationships between carbamazepine metabolites levels and prophylactic efficacy","volume":"7","author":"Kudriakova","year":"1992","journal-title":"Hum Psychopharmacol"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.0013-9580.2005.31904.x","article-title":"Potential role of drug transporters in the pathogenesis of medically intractable epilepsy","volume":"46","author":"Kwan","year":"2005","journal-title":"Epilepsia"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14728214.12.3.407","article-title":"Emerging drugs for epilepsy","volume":"12","author":"Kwan","year":"2007","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrn1728","article-title":"Drug resistance in brain diseases and the role of drug efflux transporters","volume":"6","author":"Loscher","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0009-9236(97)90027-8","article-title":"Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine","volume":"62","author":"Lown","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.neuropharm.2008.08.032","article-title":"Several major antiepileptic drugs are substrates for human P-glycoprotein","volume":"55","author":"Luna-Tortos","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1528-1167.2005.00265.x","article-title":"A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine","volume":"46","author":"Marchi","year":"2005","journal-title":"Epilepsia"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/0023210-200923010-00005","article-title":"Eslicarbazepine acetate","volume":"23","author":"McCormack","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.pnpbp.2008.03.018","article-title":"MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression","volume":"32","author":"Mihaljevic Peles","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB38|cit38","first-page":"199","article-title":"Treatment of resistant schizophrenia with valproate and neuroleptic drugs","volume":"11","author":"Morinigo","year":"1989","journal-title":"Hillside J Clin Psychiatry"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2125.2001.01359.x","article-title":"Carbamazepine is not a substrate for P-glycoprotein","volume":"51","author":"Owen","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archpsyc.1983.04390010083010","article-title":"Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response","volume":"40","author":"Post","year":"1983","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1097\/00001756-200111160-00037","article-title":"P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain","volume":"12","author":"Potschka","year":"2001","journal-title":"Neuroreport"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1528-1167.2006.00504.x","article-title":"Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy","volume":"47","author":"Rambeck","year":"2006","journal-title":"Epilepsia"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/mp0500871","article-title":"P-glycoprotein recognition of substrates and circumvention through rational drug design","volume":"3","author":"Raub","year":"2006","journal-title":"Mol Pharm"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0920-1211(98)00106-5","article-title":"Clinical aspects and biological bases of drug-resistant epilepsies","volume":"34","author":"Regesta","year":"1999","journal-title":"Epilepsy Res"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1523\/JNEUROSCI.22-14-05833.2002","article-title":"Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance","volume":"22","author":"Rizzi","year":"2002","journal-title":"J Neurosci"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1021\/jm021012t","article-title":"Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery","volume":"46","author":"Schwab","year":"2003","journal-title":"J Med Chem"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1525-5050(02)00511-5","article-title":"P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice","volume":"3","author":"Sills","year":"2002","journal-title":"Epilepsy Behav"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB48|cit48","first-page":"236","volume-title":"Antiepileptic Drugs","author":"Spina","year":"2002"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1021\/mp800122b","article-title":"Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay","volume":"6","author":"Thiel-Demby","year":"2009","journal-title":"Mol Pharm"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1157.1995.tb01657.x","article-title":"MDR1 gene expression in brain of patients with medically intractable epilepsy","volume":"36","author":"Tishler","year":"1995","journal-title":"Epilepsia"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0893-133X(99)00095-0","article-title":"Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption","volume":"22","author":"Uhr","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0092-8674(00)81370-7","article-title":"MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine","volume":"87","author":"van Helvoort","year":"1996","journal-title":"Cell"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2710.2003.00487.x","article-title":"Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors","volume":"28","author":"Wang","year":"2003","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijpharm.2007.12.024","article-title":"Application and limitation of inhibitors in drug-transporter interactions studies","volume":"356","author":"Wang","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/jpet.102.046532","article-title":"Inhibition of P-glycoprotein by newer antidepressants","volume":"305","author":"Weiss","year":"2003a","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/jpet.103.054197","article-title":"Interaction of antiepileptic drugs with human P-glycoprotein in vitro","volume":"307","author":"Weiss","year":"2003b","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1081\/CLT-120015836","article-title":"Carbamazepine poisoning: elimination kinetics and quantitative relationship with carbamazepine 10,11-epoxide","volume":"40","author":"Winnicka","year":"2002","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00003088-200140030-00002","article-title":"The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein","volume":"40","author":"Zhang","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1528-1167.2011.03140.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.lfs.2010.04.008","article-title":"In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein","volume":"86","author":"Zhang","year":"2010","journal-title":"Life Sci"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2011.03140.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1528-1167.2011.03140.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T02:49:09Z","timestamp":1637894949000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2011.03140.x"}},"subtitle":["Pgp Transport of Carbamazepine Analogs"],"short-title":[],"issued":{"date-parts":[[2011,6,21]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03140.x","relation":{},"ISSN":["0013-9580"],"issn-type":[{"value":"0013-9580","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6,21]]}}}